These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36461940)

  • 81. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
    Eloy P; Le Grand R; Malvy D; Guedj J
    EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087
    [No Abstract]   [Full Text] [Related]  

  • 82. Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo.
    Li Y; Liu M; Yan Y; Wang Z; Dai Q; Yang X; Guo X; Li W; Chen X; Cao R; Zhong W
    Viruses; 2022 May; 14(6):. PubMed ID: 35746614
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Lethal mutagenesis as an antiviral strategy.
    Swanstrom R; Schinazi RF
    Science; 2022 Feb; 375(6580):497-498. PubMed ID: 35113690
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Khoo SH; FitzGerald R; Saunders G; Middleton C; Ahmad S; Edwards CJ; Hadjiyiannakis D; Walker L; Lyon R; Shaw V; Mozgunov P; Periselneris J; Woods C; Bullock K; Hale C; Reynolds H; Downs N; Ewings S; Buadi A; Cameron D; Edwards T; Knox E; Donovan-Banfield I; Greenhalf W; Chiong J; Lavelle-Langham L; Jacobs M; Northey J; Painter W; Holman W; Lalloo DG; Tetlow M; Hiscox JA; Jaki T; Fletcher T; Griffiths G;
    Lancet Infect Dis; 2023 Feb; 23(2):183-195. PubMed ID: 36272432
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice.
    Jeong JH; Chokkakula S; Min SC; Kim BK; Choi WS; Oh S; Yun YS; Kang DH; Lee OJ; Kim EG; Choi JH; Lee JY; Choi YK; Baek YH; Song MS
    Antiviral Res; 2022 Dec; 208():105430. PubMed ID: 36209984
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study.
    Zheng Q; Bao C; Ji Y; Li P; Ma Z; Wang X; Meng Q; Pan Q
    Sci Rep; 2023 Apr; 13(1):5474. PubMed ID: 37016035
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Synthesis of Novel
    Amblard F; LeCher JC; De R; Goh SL; Li C; Kasthuri M; Biteau N; Zhou L; Tber Z; Downs-Bowen J; Zandi K; Schinazi RF
    Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145365
    [TBL] [Abstract][Full Text] [Related]  

  • 89. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
    Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S
    In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
    Radcliffe C; Palacios CF; Azar MM; Cohen E; Malinis M
    Am J Transplant; 2022 Oct; 22(10):2458-2463. PubMed ID: 35583664
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Immunosuppressants exert differential effects on pan-coronavirus infection and distinct combinatory antiviral activity with molnupiravir and nirmatrelvir.
    Wang Y; Li P; Lavrijsen M; Rottier RJ; den Hoed CM; Bruno MJ; Kamar N; Peppelenbosch MP; de Vries AC; Pan Q
    United European Gastroenterol J; 2023 Jun; 11(5):431-447. PubMed ID: 37226653
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The Long View on COVID-19 Theranostics and Oral Antivirals: Living with Endemic Disease and Lessons from Molnupiravir.
    Al-Taie A; Denkdemir FR; Sharief Z; Buyuk AS; Şardaş S
    OMICS; 2022 Jun; 26(6):324-328. PubMed ID: 35580151
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Molnupiravir for SARS-CoV-2 infection: Public health and policy implications.
    Gray EJ; Nguyen-Van-Tam JS
    J Infect; 2023 Feb; 86(2):121-122. PubMed ID: 36717180
    [No Abstract]   [Full Text] [Related]  

  • 94. Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101.
    Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
    J Pharm Biomed Anal; 2023 Sep; 234():115499. PubMed ID: 37302376
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
    Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y
    Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Johnson DM; Brasel T; Massey S; Garron T; Grimes M; Smith J; Torres M; Wallace S; Villasante-Tezanos A; Beasley DW; Comer JE
    Antiviral Res; 2023 Jan; 209():105492. PubMed ID: 36535309
    [TBL] [Abstract][Full Text] [Related]  

  • 97. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients.
    Hau RK; Wright SH; Cherrington NJ
    Clin Transl Sci; 2022 Jul; 15(7):1599-1605. PubMed ID: 35505633
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Highly sensitive high-performance thin-layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations.
    Saraya RE; Deeb SE; Salman BI; Ibrahim AE
    J Sep Sci; 2022 Jul; 45(14):2582-2590. PubMed ID: 35583051
    [TBL] [Abstract][Full Text] [Related]  

  • 99. β-d-
    Urakova N; Kuznetsova V; Crossman DK; Sokratian A; Guthrie DB; Kolykhalov AA; Lockwood MA; Natchus MG; Crowley MR; Painter GR; Frolova EI; Frolov I
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29167335
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Could a popular antiviral supercharge the pandemic?
    Service RF
    Science; 2023 Feb; 379(6632):526. PubMed ID: 36758089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.